Top advances of the year: Hepatobiliary cancers.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36692965.
- Also identified by DOI 10.1002/cncr.34652.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This commentary reviews top advances in hepatobiliary cancer research in 2021-2022, focusing on leveraging immunotherapeutics in combination with other therapies earlier in the disease course and targeted to patient's individualized biomarkers that may predict response or resistance to checkpoint inhibitors.
Medical subject headings
- Liver Neoplasms
- Biliary Tract Neoplasms
- Carcinoma, Hepatocellular